Back to search results

CYP2C19 Genetic Testing for Stroke Patients

This study is looking at how a rapid genetic test can help doctors choose the best blood thinner for patients who have had an acute ischemic stroke (a stroke caused by a blood clot). After this type of stroke, patients often receive two blood thinners, including clopidogrel. However, clopidogrel is less effective in some people due to differences in their DNA that affect an enzyme called CYP2C19. This study will use a genetic test to identify these differences. The goal is to see how well this rapid genetic testing can be put into practice at the University of Virginia Health and if it changes how doctors prescribe dual antiplatelet therapy (two blood thinners). You may be able to join if you are at least 18 years old, have symptoms of an acute ischemic stroke or transient ischemic attack (mini-stroke), and meet other criteria. The study aims to measure the percentage of eligible patients who get genotyped and how quickly the results are available. The current recruitment status is unclear.

Study design
This is an observational study, meaning researchers will observe what happens without giving specific treatments. It plans to enroll 350 participants.
What's involved
You will have a blood sample collected for genetic testing. The genotype result will be entered into your electronic health record.
Compensation
Not stated in the trial record.
Follow-up
The study measures outcomes at the time of your hospital discharge (approximately 1-5 days) and up to 21 days after your blood draw.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06292117

Implementation of Onsite Rapid CYP2C19 Assay for Genotype Guided Dual Antiplatelet Therapy After Acute Ischemic Stroke

Recruiting
Not specifiedAges 18+Observational
University of Virginia
~350 participants
Updated 2026-05-06 on ClinicalTrials.gov
What's tested:CYP2C19 Genotype

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of patients discharged from University of Virginia (UVA) Health on dual antiplatelet therapy with a diagnosis of AIS/TIA meeting eligibility criteria upon presentation that are successfully genotyped
Measured over At time of participant discharge from hospital; approximately 1-5 days
+1 more outcome measured

Conditions

Ischemic Stroke
CYP2C19 Polymorphism

Explore related trials

Ischemic StrokeTransient Ischemic Attack

Where it's being run

1 sites across 1 states
Virginia1

Study leadership

  • Rachael M Stone, PharmD · PRINCIPAL_INVESTIGATOR · University of Virginia

Who to contact

Andrew Weko, MPH
[email protected]
434-297-6777
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Men and women at least 18 years of age
Presenting with symptoms of acute ischemic stroke or transient ischemic attack and without contraindications to dual antiplatelet therapy at time of clinical research coordinator screening
Presenting within 24 of symptom onset; or, within 24-96 hours of symptom onset IF planned to receive or already on dual antiplatelet therapy

Exclusion

Receiving therapeutic anticoagulation or clear indication for initiation of anticoagulation after event (e.g., known atrial fibrillation)
History of allogeneic bone marrow transplant
History of liver transplant
Subject who is unable to consent and does not have a surrogate available to consent on their behalf

What this trial measures

  • Percentage of patients discharged from University of Virginia (UVA) Health on dual antiplatelet therapy with a diagnosis of AIS/TIA meeting eligibility criteria upon presentation that are successfully genotypedAt time of participant discharge from hospital; approximately 1-5 days
  • Average turnaround time of genotype result from time of collection of blood sample to time result is entered into the electronic health recordFrom time of participant blood draw up to 21 days after